Skip to main navigation
  • mail icon
  • fb icon
  • linkedin icon

Eiger - Header Menu

  • About
    • Team
  • Investors
    • Stock Information
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Shareholder Services
    • Analyst Coverage
  • Programs
    • Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
    • Peginterferon Lambda for Hepatitis Delta Virus (HDV) Infection
    • Avexitide for Post-Bariatric Hypoglycemia (PBH)
    • Avexitide for Congenital Hyperinsulinism (CHI)
  • Resources
    • Expanded Access Policy
    • Contact Us
    • Privacy Policy
    • Terms of Use
  • mail icon
  • fb icon
  • linkedin icon

Eiger - Header Menu

  • About
    • Team
  • Investors
    • Stock Information
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Shareholder Services
    • Analyst Coverage
  • Programs
    • Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
    • Peginterferon Lambda for Hepatitis Delta Virus (HDV) Infection
    • Avexitide for Post-Bariatric Hypoglycemia (PBH)
    • Avexitide for Congenital Hyperinsulinism (CHI)
  • Resources
    • Expanded Access Policy
    • Contact Us
    • Privacy Policy
    • Terms of Use

Investors

Press Releases

Date
Latest Press Release

September 1, 2020

Eiger Bio to Participate in September 2020 Investor Conferences

August 31, 2020

Eiger Announces Peginterferon Lambda - Lonafarnib Combination End of Treatment Results from Phase 2 LIFT HDV Study in Late Breaker Session at The Digital International Liver Congress™ 2020

August 6, 2020

Eiger BioPharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update

August 3, 2020

Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor Conferences

May 29, 2020

Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020

May 26, 2020

Eiger to Present at Jefferies Virtual Healthcare Conference 2020

May 19, 2020

Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies

May 7, 2020

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

April 30, 2020

Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda

April 27, 2020

Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »

Eiger - Shareholder Tools

  • Print Page
  • Contact Us
  • RSS Feeds
  • Email Alerts
  • IR Contacts

Contact Us

Use of this website is governed by the Terms and Conditions and Privacy Policy.

Copyright ©2019 Eiger BioPharmaceuticals. All Rights Reserved. 06/19 XX-XX-XXXX

Contact Us

Eiger Logo

Use of this website is governed by the Terms and Conditions and Privacy Policy.

Copyright ©2019 Eiger BioPharmaceuticals. All Rights Reserved. 06/19 XX-XX-XXXX